 |
|
|
 |
.TOP NEWS
SIO2023: IO Essentials Scholarship Application Portal Now Open
The SIO2023 IO Essentials Scholarship application portal is now open. Don't forget to take advantage of this opportunity to access top-tier education, networking opportunities with IO luminaries, and continues professional development. To apply, you will need to complete the application form and submit:
- Current CV
- Letter of Recommendation from and IO/IR Program Director or Faculty Member
- Case Submission
Applications will close on 19 September, 2022 and recipients will be notified in October 2022.
|
|
SIO23: Now Accepting Abstract Submissions
 SIO has begun accepting abstract submissions. Share your research with more than 600 professionals in the global IO community and gain recognition from your peers. Abstracts may be submitted in the following categories:
| |
|
|
- Basic Science
- Genitourinary
- Guidance & Targeting
- HCC
|
- Imaging
- Liver Metastases
- Technology
- Thoracic
|
|
|
|
The Deadline to submit your abstract will be 15 September 2022, and selected presenters will be notified in October 2022.
|
|
Renew Your SIO Membership Today: Extended Membership Option Now Available!
 SIO members and volunteers are working to move the field of IO forward in research and education to solidify IO as the fourth pillar of cancer therapy. You don't want to miss out on what SIO has in store.
From member exclusive education opportunities, brand new advocacy events, and new abstract scholarship opportunities, SIO serves as the premier society for IO professionals to network and advance their practice this fall and beyond.
Benefit from the convenience of joining now—and don't worry about membership until 2024! Renew now and immediately gain access to members-only savings and professional opportunities.
|
|
|
|
 |
|
Outcomes in the first 100 patients treated with the OsteoCool™ Radiofrequency Ablation System from the OPuS One trial were recently published in the November edition of the Journal of Vascular and Interventional Radiology (JVIR). Learn more about the largest prospective study in radiofrequency ablation for bone metastases.
|
|
.INDUSTRY NEWS
Surgical and Locoregional Therapy of HCC: TACE
Liver Cancer via PubMed
Transcatheter arterial chemoembolization (TACE) is performed worldwide for patients with intermediate-stage hepatocellular carcinoma (HCC). TACE has produced survival advantages in two randomized controlled trials and a meta-analysis, and is currently the mainstay of treatment for this stage of HCC.
|
|
Transarterial Chemoembolization: Modalities, Indication, and Patient Selection
Journal of Hepatology via PubMed
Transarterial chemoembolization (TACE) is the standard of care for patients with intermediate stage hepatocellular carcinoma (BCLC B). Further improvement of the use of TACE was the subject of intense clinical research over the past years. The introduction of DEB-TACE brought more technical standardization and reduction of TACE related toxicity.
|
|
Development of TACE Refractoriness Scores in Hepatocellular Carcinoma
Frontiers in Molecular Biosciences via PubMed
This study sought to identify the independent risk factors for transarterial embolization (TACE) refractoriness and to develop a novel TACE refractoriness score and nomogram for predicting TACE refractoriness in patients with hepatocellular carcinoma (HCC).
|
|
|
|
|
|
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063 |
